Summary
A switch from one drug or route of administration to another is common practice during long term opioid therapy in patients with chronic cancer pain.
A change in drug, which is known as ‘opioid rotation’ or ‘sequential opioid trials,’ has become an accepted strategy to address an initially poor response to a specific opioid. The approach derives from the observation that there is large individual variation in the pattern of adverse effects produced by different opioids, and that the balance between analgesia and adverse effects may be improved following a switch to an alternative drug. A change of route is usually driven by practical considerations, typically the loss of the oral route.
Regardless of the indication, a well tolerated and effective conversion from one opioid or route of administration to another requires an understanding of administration guidelines based on relative potency. The equi-analgesic dose table provided in this review codifies the results of previous studies that have evaluated the relative potencies across drugs or routes. To use the information contained in this table, the clinician must understand its derivation, limitations and practical application. The equi-analgesic dose ratios largely represent average data from controlled single-dose studies in selected populations. These values are tentative in the setting of long term administration of the drugs to medically ill patients. The ratios also fail to account for the possibility of incomplete crosstolerance, which would render the new drug more potent than anticipated, and the impact on administration of either unrelieved pain or a predisposition to opioid toxicity.
To accommodate these uncertainties, guidelines for the use of the equi-analgesic dose table include a standard reduction in the calculated equi-analgesic dose, which is then further adjusted based on the clinical characteristics of the patient. The new dose is then the starting point for the process of dose titration. These guidelines must be further adapted for two special cases: a switch to methadone (which has been observed to yield a potency much greater than expected) and conversions that involve the transdermal fentanyl system.
Similar content being viewed by others
References
World Health Organization. Cancer pain relief and palliative care. Geneva: World Health Organization, 1996
Jacox A, Carr DB, Payne R, et al. Management of cancer pain. Clinical practice guideline. No. 9. AHCPR publication no. 94-0592. Rockville (MD): Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Health Service, 1994
Schug SA, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990; 5: 27–32
Schug SA, Zech D, Grond S, et al. A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992; 7: 259–66
Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO method for cancer pain relief. Cancer 1990; 59: 850–6
Kaplan R, Conant M, Cundiff D, et al. Sustained-release morphine sulfate in the management of pain associated with acquired immune deficiency syndrome. J Pain Symptom Manage 1996; 12: 150–60
Portenoy RK. Opioids for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996; 11: 203–17
Cherny NI, Portenoy RK. Systemic drugs for cancer pain. Pain Digest 1995; 5: 245–63
Levy M. Pharmacologic treatment of cancer pain. N Engl J Med 1996; 335: 1124–32
Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990; 43: 273–86
Galer BS, Coyle N, Pasternak GW, et al. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87–91
Cherny NI, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995; 76: 1288–93
de Stoutz N, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378–84
MacDonald N, Der L, Allan S, et al. Opioid hyper-excitability: the application of alternate opioid therapy. Pain 1993; 53: 353–5
Houde RW, Wallenstein SL, Beaver WT. Evaluation of analgesics in patients with cancer pain. In: Lasagna L, editor. International encyclopedia of pharmacology and therapeutics. Oxford: Pergamon Press, 1966: 59–98
Dunbar PJ, Chapman CR, Buckley FP, et al. Clinical analgesia equivalence for morphine and hydromorphone with prolonged PCA. Pain 1996; 68: 269–70
Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996; 64: 527–34
Kaiko RF. Commentary: equianalgesic dose ratio of intramuscular/oral morphine, 1:6 versus 1:3. In: Foley KM, Inturrisi CE, editors. Advances in pain research and therapy. Vol. 8. New York: Raven Press, 1986: 87–94
Bruera EB, Pereira J, Watanabe S, et al. Systemic opioid therapy for chronic cancer pain: practical guidelines for converting drugs and routes. Cancer 1996; 78(4): 852–7
Cole L, Hanning CD. Review of the rectal use of opioids. J Pain Symptom Manage 1990; 5: 118–26
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273–82
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Derby, S., Chin, J. & Portenoy, R.K. Systemic Opioid Therapy for Chronic Cancer Pain. Mol Diag Ther 9, 99–109 (1998). https://doi.org/10.2165/00023210-199809020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199809020-00003